2013
Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty
Dudek D, Mehran R, Dziewierz A, Witzenbichler B, Brodie BR, Kornowski R, Fahy M, Lansky AJ, Rakowski T, Legutko J, Bryniarski L, Stone GW. Impact of advanced age on the safety and effectiveness of paclitaxel‐eluting stent implantation in patients with ST‐segment elevation myocardial infarction undergoing primary angioplasty. Catheterization And Cardiovascular Interventions 2013, 82: 869-877. PMID: 23359554, DOI: 10.1002/ccd.24813.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPaclitaxel-eluting stent implantationPrimary PCIBare metal stentsElevation myocardial infarctionYears of ageStent implantationOlder patientsMyocardial infarctionLower riskIschemic target vessel revascularizationMajor adverse cardiac eventsHORIZONS-AMI studyHORIZONS-AMI trialReduction of MACEAdverse cardiac eventsTarget vessel revascularizationClinical end pointsPercutaneous coronary interventionLong-term resultsImpact of ageCause deathMajor bleedingPrimary angioplasty
2012
Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Yu J, Mehran R, Dangas GD, Claessen BE, Baber U, Xu K, Parise H, Fahy M, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2012, 5: 1231-1238. PMID: 23257371, DOI: 10.1016/j.jcin.2012.07.016.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionLow-dose aspirinElevation myocardial infarctionHigh-dose aspirinPrimary PCIHORIZONS-AMI trialPercutaneous coronary interventionMyocardial infarctionMajor bleedingCoronary interventionIschemic target vessel revascularizationMajor adverse cardiovascular eventsCoronary artery bypass surgeryLong-term patient outcomesAdverse ischemic eventsAdverse cardiovascular eventsDose of aspirinTarget vessel revascularizationArtery bypass surgeryHistory of hypertensionPremature coronary diseaseLong-term outcomesIschemic benefitAspirin dose
2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore lab
2006
Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial)
Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O’Neill W, Lansky AJ, Griffin JJ, Investigators C. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non–ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). The American Journal Of Cardiology 2006, 98: 331-337. PMID: 16860018, DOI: 10.1016/j.amjcard.2006.01.102.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAnticoagulantsBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleElectrocardiographyFemaleFollow-Up StudiesHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMyocardial InfarctionPlatelet Glycoprotein GPIIb-IIIa ComplexStentsStroke VolumeSurvival RateTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIMyocardial Infarction (TIMI) grade 3 flowIschemic target vessel revascularizationGrade 3 flowOutcomes of patientsTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationAcute MICoronary interventionMyocardial infarctionAcute ST-segment elevation myocardial infarctionSegment elevation acute myocardial infarctionMajor adverse cardiac eventsElevation acute myocardial infarctionOngoing chest painSimilar late mortalityAdverse cardiac eventsElevation myocardial infarctionST-segment elevationAcute myocardial infarctionHigher ejection fractionPostprocedural ThrombolysisRelationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction
Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW, Investigators F. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. American Heart Journal 2006, 151: 1288-1295. PMID: 16781238, DOI: 10.1016/j.ahj.2005.08.017.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIST-segment resolutionMyocardial infarctionReperfusion successVentricular functionClinical outcomesCollateral flowAnterior infarctionMyocardial perfusionArtery locationFinal TIMI 3 flowIschemic target vessel revascularizationMajor adverse cardiac eventsReduced left ventricular functionRight coronary artery distributionPrimary percutaneous revascularizationAdverse cardiac eventsBaseline clinical characteristicsTarget vessel revascularizationTIMI 3 flowMyocardial blush gradePowerful independent predictorPercutaneous coronary intervention
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictorsImpact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, Mehran R, Fahy M, Brodie BR, Grines CL, Investigators F. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American Journal Of Cardiology 2005, 95: 1-7. PMID: 15619385, DOI: 10.1016/j.amjcard.2004.08.054.Peer-Reviewed Original ResearchConceptsTarget vessel revascularizationAcute myocardial infarctionPrimary end pointDiabetic patientsNondiabetic patientsPrimary angioplastyDiabetes mellitusStent implantationMyocardial infarctionIschemic target vessel revascularizationEnd pointRoutine stent implantationAbciximab useComposite incidenceReperfusion modalityRoutine stentingAngiographic restenosisVessel revascularizationBalloon angioplastyImproved outcomesPatientsAngioplastyAbciximabDiabetesBeneficial effects
2003
Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial
Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tcheng JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, Mehran R, Investigators C. Outcomes of optimal or “stent-like”balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 42: 971-977. PMID: 13678914, DOI: 10.1016/s0735-1097(03)00911-2.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationRoutine stentingRoutine stent placementStent implantationStent placementPrimary percutaneous transluminal coronary angioplastyComposite adverse event rateLate Angioplasty Complications (CADILLAC) trialRoutine stent implantationAdverse event ratesTransluminal coronary angioplastyRelevant treatment modalitiesRate of deathCADILLAC trialControlled AbciximabEligible lesionsAngiographic restenosisVessel revascularizationComplications TrialCoronary angioplastyDiameter stenosisPTCA results